Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 12 months
Awards & highlights
Study Summary
This trial will test the safety and effectiveness of MEB-1170 in healthy people to see if it is safe and tolerated.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, approximately 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety and Tolerability of Single Ascending Doses of MEB-1170 for Fasting SAD and MAD laboratory assessments for blood chemistry
Safety and Tolerability of Single and Multiple Ascending Doses of MEB-1170 assess subjects with a physical exam
Safety and Tolerability of Single and Multiple Ascending Doses of MEB-1170 assess vital signs
+6 moreSecondary outcome measures
To assess the pharmacodynamic (PD) effect of analgesia using a Cold Pressor Test following single and multiple oral doses of MEB-1170
To assess the pharmacodynamic (PD) response of Pupillometry following single and multiple oral doses of MEB-1170
To assess the pharmacodynamic (PD) response using capnography following single and multiple oral doses of MEB-1170
+5 moreTrial Design
32Treatment groups
Experimental Treatment
Placebo Group
Group I: B4 MEB-1170Experimental Treatment1 Intervention
MAD 400 mg MEB-1170 cohort
Group II: B3 MEB-1170Experimental Treatment1 Intervention
MAD 200 mg MEB-1170 cohort
Group III: B2 MEB-1170Experimental Treatment1 Intervention
MAD 100 mg MEB-1170 cohort
Group IV: B1 MEB-1170Experimental Treatment1 Intervention
MAD 60 mg MEB-1170 cohort
Group V: A5b MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 400 mg dose cohort
Group VI: A5a MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 Sentinel 400 mg Dose
Group VII: A4a MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 Sentinel 200 mg Dose
Group VIII: A3b MEB-1170 Fed StateExperimental Treatment1 Intervention
Single MEB-1170 120 mg dose cohort in Fed State
Group IX: A3b MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 120 mg dose cohort
Group X: A3a MEB-1170 Fed StateExperimental Treatment1 Intervention
Single Sentinel 120 mg Dose of MEB-1170 in Fed State
Group XI: A3a MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 Sentinel 120 mg Dose
Group XII: A2b MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 60 mg dose cohort
Group XIII: A2a MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 Sentinel 60 mg Dose
Group XIV: A1b MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 20 mg dose cohort
Group XV: A1a MEB-1170Experimental Treatment1 Intervention
Single MEB-1170 Sentinel 20 mg Dose
Group XVI: B4 PlaceboPlacebo Group1 Intervention
MAD Placebo 400 mg comparator cohort of MEB-1170
Group XVII: A3a Placebo Fed StatePlacebo Group1 Intervention
Single Sentinel Placebo Comparator for 120 mg Dose of MEB-1170 in Fed State
Group XVIII: A1a PlaceboPlacebo Group1 Intervention
Single Sentinel Placebo Comparator for 20 mg Dose of MEB-1170
Group XIX: A1b PlaceboPlacebo Group1 Intervention
Single Placebo comparator for 20 mg dose cohort of MEB-1170
Group XX: A2a PlaceboPlacebo Group1 Intervention
Single Sentinel Placebo Comparator for 60 mg Dose of MEB-1170
Group XXI: A2b PlaceboPlacebo Group1 Intervention
Single Placebo comparator for 60 mg dose cohort of MEB-1170
Group XXII: A3a PlaceboPlacebo Group1 Intervention
Single Sentinel Placebo Comparator for 120 mg Dose of MEB-1170
Group XXIII: A3b PlaceboPlacebo Group1 Intervention
Single Placebo comparator for 120 mg dose cohort of MEB-1170
Group XXIV: A4a PlaceboPlacebo Group1 Intervention
Single Sentinel Placebo Comparator for 200 mg Dose of MEB-1170
Group XXV: A4b PlaceboPlacebo Group1 Intervention
Single Placebo comparator for 200 mg dose cohort of MEB-1170
Group XXVI: A4b MEB-1170Placebo Group1 Intervention
Single MEB-1170 200 mg dose cohort
Group XXVII: A5a PlaceboPlacebo Group1 Intervention
Single Sentinel Placebo Comparator for 400 mg Dose of MEB-1170
Group XXVIII: A5b PlaceboPlacebo Group1 Intervention
Single Placebo comparator for 400 mg dose cohort of MEB-1170
Group XXIX: B1 PlaceboPlacebo Group1 Intervention
MAD Placebo 60 mg comparator cohort of MEB-1170
Group XXX: B2 PlaceboPlacebo Group1 Intervention
MAD Placebo 100 mg comparator cohort of MEB-1170
Group XXXI: B3 PlaceboPlacebo Group1 Intervention
MAD Placebo 200 mg comparator cohort of MEB-1170
Group XXXII: A3b Placebo Fed StatePlacebo Group1 Intervention
Single Placebo comparator for 120 mg dose cohort of MEB-1170 in Fed State
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Mebias Discovery, IncLead Sponsor
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You should not have used over-the-counter medications like painkillers, herbal remedies, supplements, or vitamins in the week leading up to the study. The only exception is if you have taken acetaminophen (up to 4g per day) for mild pain relief.You can handle the cold pressor test without any problems.You have a history or currently have a serious heart rhythm problem.You have a history of drug addiction or using drugs through injections for recreational purposes in the past 5 years.You have had a serious infection in the past month or have needed strong antibiotics for an infection in the past six months.You have trouble swallowing pills or experience difficulty in swallowing.
Research Study Groups:
This trial has the following groups:- Group 1: B4 MEB-1170
- Group 2: A3a MEB-1170 Fed State
- Group 3: B4 Placebo
- Group 4: A3a Placebo Fed State
- Group 5: A1a Placebo
- Group 6: A1a MEB-1170
- Group 7: A1b Placebo
- Group 8: A1b MEB-1170
- Group 9: A2a Placebo
- Group 10: A2a MEB-1170
- Group 11: A2b Placebo
- Group 12: A2b MEB-1170
- Group 13: A3a Placebo
- Group 14: A3a MEB-1170
- Group 15: A3b Placebo
- Group 16: A3b MEB-1170
- Group 17: A4a Placebo
- Group 18: A4a MEB-1170
- Group 19: A4b Placebo
- Group 20: A4b MEB-1170
- Group 21: A5a Placebo
- Group 22: A5a MEB-1170
- Group 23: A5b Placebo
- Group 24: A5b MEB-1170
- Group 25: B1 Placebo
- Group 26: B1 MEB-1170
- Group 27: B2 Placebo
- Group 28: B2 MEB-1170
- Group 29: B3 Placebo
- Group 30: B3 MEB-1170
- Group 31: A3b Placebo Fed State
- Group 32: A3b MEB-1170 Fed State
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Am I eligible to take part in this experiment?
"To be considered for this clinical trial, eligible individuals must have experienced pain and fit into the age bracket of 18 to 55 years. This study is looking to enrol 72 participants in total."
Answered by AI
How has A1a MEB-1170 been evaluated for safety in clinical trials?
"Our team at Power assessed A1a MEB-1170's safety as a "1" since the trial is in Phase 1, and thus has restricted evidence backing both its efficacy and security."
Answered by AI
Is this research endeavor accommodating elderly participants?
"The parameters of this medical study dictate that eligible patients must fall within the 18 to 55 age range. However, there are 76 trials available for minors and 253 studies specifically targeting elderly individuals."
Answered by AI
What is the main aim of this clinical experiment?
"The objective of this 12-month trial is to measure both the safety and tolerability of MEB-1170 via single ascending doses through fasting SAD and MAD laboratory assessments. Secondary objectives include determining a single or multiple oral dose pharmacokinetic profile, assessing how food impacts PK parameters such as AUC0-24 and Cmax in healthy subjects, and finally evaluating the efficacy of MEB-1170 over time."
Answered by AI
Are any additional volunteers being recruited for this trial?
"Affirmative. According to the information available on clinicaltrials.gov, this trial is actively seeking participants and was initially posted on November 15th 2022. It has since been updated as of February 17th 2023 with a target enrollment size of 72 individuals at one medical centre."
Answered by AI
How many participants are partaking in this research?
"Indeed, the information on clinicaltrials.gov reveals that this trial is actively recruiting patients. The protocol was first published on November 15th 2022 and most recently updated on February 17th 2023. 72 enrollees are necessary for completion at one medical site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger